@Arthur_Aung
Account based inUnited States
About this account
- Account based in
- United States
- Connected via
- United States App Store
Account-level information from X, not a live location or the device used for a specific post.
Hematology Oncology Fellow | Northwell Health Northshore/LIJ Hospital
New York, USA
Joined July 2012
- Tweets132
- Following1.4K
- Followers243
- Likes139
Arthur Aung retweeted
Claude can now break down papers like an MIT researcher.
Here are 10 insane Claude prompts that turn dense research papers into simple summaries, diagrams, limitations, experiments, and future research ideas in minutes (Save this)
Excited to share our systematic review and meta-analysis of standard- versus reduced-dose sotorasib in KRAS G12C-mutated NSCLC, now published in @JCOOP_ASCO
Reduced dosing did not appear to substantially compromise efficacy, supporting dose optimization efforts aligned with FDA Project Optimus.
Grateful to my coauthors for their contributions to this work.
@NagashreeSeeth1 @DivyaReddyMD @KRASKickers
#KRAS #ProjectOptimus #LCSM
ascopubs.org/doi/10.1200/OP-…
One question that emerged from this work:
Should our assessment of tolerability extend beyond adverse events to include a patient's ability to remain on therapy long enough to derive benefit?
#ProjectOptimus #LCSM
Completely agree. Tolerability is more than adverse events. If reduced toxicity allows patients to stay on treatment longer without compromising target inhibition, it may become part of the efficacy pathway itself.
Grateful to @HannahRAbrams for highlighting this concept and to @NagashreeSeeth1 for her mentorship on the work behind these observations.
In this regard, drugs like Zofran, interventions like exercise, etc, are some of the most powerful cancer Rx we have. So kudos @Arthur_Aung on this study - higher upfront dose intensity is not always most effective if can’t consistently deliver it safely!
Excited to see this work presented at #ASCO26. Patients with pre-existing autoimmune disease remain underrepresented in immunotherapy trials, and real-world data are critical to informing treatment decisions. Looking forward to seeing the results and discussion.
@NehemiasGuevar5 @dominicandoc2 @oncodaily
Congrats to @NehemiasGuevar5 & team #ASCO26
Key takeaways for oncologists:
🔹 Autoimmune disease ≠ automatic exclusion from ICIs
🤔 Requires careful toxicity monitoring & patient selection
🤝 Strong oncology + rheumatology collaboration is critical
🔹 Shared decision-making remains essential
Important real-world data for everyday practice 💉🫁 #Immunotherapy @ASCOTECAG @hemeoncfellow @HemOncFellows @ASCO
Arthur Aung retweeted
Congrats to @NehemiasGuevar5 & team #ASCO26
Key takeaways for oncologists:
🔹 Autoimmune disease ≠ automatic exclusion from ICIs
🤔 Requires careful toxicity monitoring & patient selection
🤝 Strong oncology + rheumatology collaboration is critical
🔹 Shared decision-making remains essential
Important real-world data for everyday practice 💉🫁 #Immunotherapy @ASCOTECAG @hemeoncfellow @HemOncFellows @ASCO
Join @NehemiasGuevar5 at #ASCO26 as he presents Poster 81:
“Survival outcomes in individuals with cancer and pre-existing autoimmune disease receiving immune checkpoint inhibitors
📍 Hall A
🗓 June 1
⏰ 9:00 AM–12:00 PM
Thank you @NarjustFlorezMD for building such a supportive community for trainees and early-career oncologists. It’s a great reminder of how much mentorship and community can shape our careers. @NehemiasGuevar5 #ASCO26
My joy and pride - the community that I once created so nobody will feel as isolated as once did.
At our yearly lunch at #ASCO26
Arthur Aung retweeted
What environmental factors may contribute to lung cancer risk beyond smoking?
Looking forward to presenting our #ASCO26 poster on ambient carbon tetrachloride exposure and lung cancer incidence in the U.S.
Abstract: asco.org/abstracts-presentat…
@NagashreeSeeth1 @NorthwellHealth
As oncology becomes increasingly complex, patient education is more important than ever.
I'm grateful for the opportunity to work with @cancerGRACE on a patient education series focused on #ThyroidCancer, covering
🧬 Targeted therapies
🩺 Treatment pathways
📈 Management of recurrent thyroid cancer
Video 30-32
youtube.com/playlist?list=PL…
Translating rapidly evolving science into practical information for patients and caregivers remains an essential part of delivering high-quality cancer care.
If you're in Chicago for #ASCO26, join us at the GRACE reception:
📍 Beatrix North
📅 May 29
🕖 7 PM
#ThyroidCancer #PatientEducation #ASCO26
@NagashreeSeeth1 @JackWestMD @AmyBickleman @NehemiasGuevar5 @oncodaily @EliLillyandCo @ASCOTECAG
Arthur Aung retweeted
Now focusing on the rapid oral abstract head and neck cancers (Monday 6/1 at 4:30 PM CT)- a fascinating line up featuring novel therapeutics and strategies-hinting towards a brighter future
Arthur Aung retweeted
I used a team of ~30 AI agents to analyze 57,603 ASCO Abstracts between 2016-2025. Here are my top 6 learnings on the past decade of oncology open.substack.com/pub/liangc…
Arthur Aung retweeted
Excited to share our new publication with @NarjustFlorezMD @MImbimbo1 @COlazagasti on lung cancer diagnosed during pregnancy — a rare and highly complex clinical scenario requiring multidisciplinary care.
frontiersin.org/journals/onc…
Arthur Aung retweeted
Conference season is upon us with poster sessions, #oralabstracts, and #grandrounds on the horizon! To help prepare, we wrote this #ASCOconnection article:
🔗 The High-Stakes Talk 🗣️ @jennifermarksmd @ASCO
In the piece, we share practical strategies to:
🔹 Lead with the core message
🔹 Make the “so what” clear
🔹 And more
Because strong science should be easy to understand, discuss, remember, and carry forward.
🙋🏾♂️What is the best presentation advice you have received or the one lesson you wish you had learned earlier?
connection.asco.org/do/high-…
#Oncology #MedEd #ASCOtips #PresentationTips #PosterPresentation #ResearchTalks
@hemeoncfellow @HemOncFellows @SNMA @LmsaNational @ASCOTECAG @OncoAlert @oncodaily
Arthur Aung retweeted
#TumorBoardTuesday
🫁 Early-stage #NSCLC is no longer just surgery ➕ chemo: Molecular testing now shapes curative-intent Tx decisions 🧬
📢Join us Tuesday, 05-05-26 at 8PM ET as @NarjustFlorezMD & @NehemiasGuevar5 🗣️EGFR+ Early #NSCLC
RT and bring others into the discussion‼️
Arthur Aung retweeted
Join us tomorrow at 8 PM ET for a deep dive into early-stage #NSCLC and #NeoADAURA @TumorBoardTues @NarjustFlorezMD @Florez_Lab @OncBrothers @COlazagasti @dominicandoc2 @oncodaily @Arthur_Aung
@guicorreiamd
@IMG_Oncologists @Shuai_WangOnc @HyeinJeon_MD @TejaVorugantiMD @OncLive
#TumorBoardTuesday
🫁 Early-stage #NSCLC is no longer just surgery ➕ chemo: Molecular testing now shapes curative-intent Tx decisions 🧬
📢Join us Tuesday, 05-05-26 at 8PM ET as @NarjustFlorezMD & @NehemiasGuevar5 🗣️EGFR+ Early #NSCLC
RT and bring others into the discussion‼️
Honored to contribute to the discussion on thyroid cancer in 2026. Thank you to @oncodaily @NagashreeSeeth1 @DrMLChua @amanda_psyrri for organizing the summit.
Highlights From How I Treat Head and Neck Cancers in 2026: OncoDaily Virtual Summit
@COlazagast @AriRosenbergMD @NagashreeSeeth1 @mdkarapetyan @drdavidpalma @amil__dr @amanda_psyrri @drdaviddwlee @imrtlee @DrMLChua
oncodaily.com/not-to-miss/he…
#OncoDaily #Oncology #Cancer #Health #Medicine #MedX #MedTwitter #HeadAndNeckCancer
Amazing panel discussion on long-term immunotherapy outcomes in NSCLC, dual checkpoint blockade, and how we still need to refine patient selection. Grateful to learn from this group
@benlevylungdoc
@lungoncdoc @RachelSanbornMD @DasMillie11 #TexasLung
